Skip to main content
Orum Therapeutics, Inc. logo

Orum Therapeutics, Inc. - Investor Relations & Filings

Listed IPO Feb 2025
Ticker · 475830 ISIN · KR7475830006 KO Professional, scientific and technical activities
Open in API
Filings indexed 92 across all filing types
Latest filing 2026-03-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 475830 · 1 venue

About Orum Therapeutics, Inc.

https://www.orumrx.com/

Orum Therapeutics is a clinical-stage biotechnology company that develops targeted protein degradation (TPD) therapeutics. The company's proprietary TPD²® platform creates a novel class of antibody-drug conjugates (ADCs), referred to as degrader-antibody conjugates (DACs). This technology combines the cell-targeting precision of antibodies with the catalytic action of protein degraders. The approach is designed to selectively deliver payloads to diseased cells to eliminate intracellular proteins that are difficult to target with conventional drugs. Orum's primary focus is on developing treatments for cancer, aiming to improve efficacy and safety over existing therapies.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 81% confidence The document is a statutory Korean filing entitled “주식매수선택권 부여에 관한 신고,” detailing the grant of stock purchase options to directors, auditors, employees, and related parties. This is not an annual or quarterly report, nor an earnings release, nor a management change notice. It is a corporate announcement concerning the issuance of equity-linked instruments (stock options), affecting the company’s capital structure. The most appropriate category is Share Issue/Capital Change (SHA).
2026-03-27 Korean
[기재정정]주주총회소집결의
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a notice of convocation (“주주총회 소집결의”) for the upcoming annual general meeting, including the meeting date, venue, record date and detailed agenda items. It is not a financial report or earnings release, nor a summary of results, but rather the formal materials sent to shareholders to inform them of meeting proposals and solicit votes. This corresponds to a Proxy Solicitation & Information Statement (PSI).
2026-03-26 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal notice and information statement for the company’s 10th Annual General Meeting (주주총회 소집공고), including agenda items, director nominations, business overviews, and voting instructions. It is not the company’s annual report (10-K), earnings release, or financial statements, but rather the packet sent to shareholders to solicit proxies and provide details on meeting proposals. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-26 Korean
[기재정정]감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It contains specific financial data, audit opinions, and financial statements for the fiscal year ending 2025-12-31. While it provides financial details, it is a structured regulatory disclosure form (DART/KIND system format) rather than the full, narrative-heavy Annual Report (10-K). It serves as the official notification of the audit results and financial summary, fitting the 'Audit Report / Information' category. FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and auditor information. While it contains audit-related data, it is a standard regulatory disclosure form used by companies to announce the filing of their audit results rather than the full, multi-page audit report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2025
2026-03-19 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Orum Therapeutics, covering the fiscal year ending December 31, 2025. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, etc.), and detailed notes. It is a comprehensive financial report rather than an announcement or a summary, fitting the definition of an Audit Report (AR). FY 2025
2026-03-19 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.